中國生物製藥(01177.HK)旗下抗凝血藥阿加曲班注射液獲批上市
格隆匯12月12日丨中國生物製藥(01177.HK)宣佈,由公司附屬公司南京正大天晴製藥有限公司開發的抗凝血藥"阿加曲班注射液",已獲中國國家藥品監督管理局頒發藥品註冊批件。該產品適用於:(1)病發48小時內的缺血性腦梗死急性期病人的神經症狀和日常活動的改善;及(2)慢性動脈閉塞症患者的四肢潰爛、靜息痛及冷感等的改善。
阿加曲班為合成的精氨酸衍生物,能抑制凝血酶的活性從而產生抗凝作用,具有起效快、作用時間短、出血傾向小、無免疫原性等優勢。阿加曲班作為抗凝血藥在國外應用於臨牀已有多年,在國內已被納入2017版國家醫保目錄。集團研製的阿加曲班注射液獲批上市,將進一步豐富集團的心腦血管用藥產品線,同時為市場提供一個具競爭力的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.